Neuralstem (NASDAQ:CUR) Upgraded at ValuEngine

ValuEngine upgraded shares of Neuralstem (NASDAQ:CUR) from a hold rating to a buy rating in a research report report published on Wednesday morning, ValuEngine reports.

CUR traded up $0.03 on Wednesday, reaching $2.18. The company’s stock had a trading volume of 80,831 shares, compared to its average volume of 192,224. Neuralstem has a 1 year low of $2.09 and a 1 year high of $27.40. The firm has a 50 day moving average of $1.49.

Neuralstem (NASDAQ:CUR) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($3.40) earnings per share for the quarter. Neuralstem had a negative return on equity of 118.28% and a negative net margin of 2,248.47%.

About Neuralstem

Neuralstem, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.

Further Reading: Why are gap-down stocks important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.